© 2025 MJH Life Sciences™ , Patient Care Online – Primary Care News and Clinical Resources. All rights reserved.
Revolutionizing Atopic Dermatitis (RAD)
RAD is where your goal to improve patients’ lives converges with meaningful discussions and groundbreaking concepts in atopic dermatitis. At this dynamic gathering, evidence drives conversations and strategies that matter are conceived, giving you an unparalleled platform to expand your skills. This year, we’re turning up the energy in Nashville. Get ready to experience Nashville’s vibrant culture and iconic music scene, right here at RAD!
RAD 2025: Nemolizumab as adjunctive therapy to topical steroids with/without topical calcineurin inhibitors provided rapid relief in moderate-to-severe atopic dermatitis.
RAD 2025: Researchers observed a marked reduction and low burden of viable S. aureus on lesional and non-lesional skin after 1 year of dupilumab treatment.
RAD 2025: Roflumilast cream significantly improved atopic dermatitis in children and adolescents through 52 weeks, offering a safe, effective treatment option.
RAD 2025: Under lebrikizumab maintenance treatment in week 16 responders, approximately 8 out of 10 achieved almost clear skin up to 3 years.
RAD 2025: Safety and tolerability of roflumilast cream 0.15% was demonstrated in a pooled subgroup analysis of phase 3 study participants unresponsive to or intolerant of previous topical therapy.
RAD 2025: This unique study design simulates the real-world use of JAK inhibitors in tailored treatment regimens with flexibility to manage AEs.
RAD 2025: More than 80% of people would want, or would consider, a test that would direct them towards a more effective therapy for their AD, according to new data.
RAD 2025: Arcutis Biotherapeutics will present promising long-term data on roflumilast cream, focused on effectiveness and safety for treating atopic dermatitis in young children.
A quick look at the states ranking highest and lowest on metrics including influenza vaccination, tetanus vaccination, HPV vaccination, and more.
The global prevalence of AD in older adults increased by 107% between 1990 and 2021, with a greater burden among women and in high sociodemographic regions.